EGFR-tested Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting
Observational Model: Cohort, Time Perspective: Retrospective
To describe patient demographic characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt. Demographic characterics include age, race,ethnicity, date of initial diagnosis, age at initial diagnosis, location of biopsy at diagnosis, extent of disease with description and location of metastatic sites, histology,and smoking history.
David R Spigel, MD
Sarah Cannon Research Institute
United States: Institutional Review Board
SCRI OUTCOMES 13
|Tennessee Oncology, PLLC||Clarksville, Tennessee 37043|